Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

    ... patients, 70% were chelated adequately mainly with deferasirox (26%) or deferasirox following deferoxamine (39%). Mortality was 70% among ...

    Research Article last updated 07/29/2014 - 12:11pm.

  2. Iron Chelation

    ... because of the need to carry around a pump. Deferasirox is a newer iron chelator that now comes in two forms (see below). Deferasirox is not recommended for people with high-risk MDS. ...

    Topic section last updated 06/23/2016 - 3:56pm.

  3. Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

    ... chronic iron overload from blood transfusions. Deferasirox has been developed as an iron-chelating agent, and unlike deferoxamine, a previously developed iron chelator, deferasirox has the advantage of oral administration. ...

    Clinical Trial last updated 04/29/2016 - 2:40pm.

  4. Iron overload in myelodysplastic syndromes: diagnosis and management.

    ... Iron chelation strategies include oral agents such as deferasirox (Exjade, Novartis Pharmaceuticals Corp, East Hanover, NJ), ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. MDS - Treatment (OLD)

    ... a small portable pump about the size of a CD player. Deferasirox ( Exjade ®) is a newer iron chelating medication that comes ... dissolved in juice or water and taken (by mouth) once a day. Deferasirox is not recommended for people with high-risk MDS. Deferasirox ...

    Topic section last updated 03/10/2016 - 11:01pm.

  6. Aristoteles Giagounidis, MD

    ... and azacitidine in myelodysplastic syndromes, deferasirox in iron overload , eltrombopag, romiplostim, and ...

    Page last updated 01/20/2012 - 3:30pm.

  7. Clinical Trial Basics

    ... These include: decitabine (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) ...

    Page last updated 03/29/2016 - 7:29pm.

  8. Clinical Trials Report for August 2015

    ... identifier: NCT01757639 Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk ... of this trial is to assess the effect of treatment with deferasirox combined with erythropoietin vs. erythropoietin alone on ...

    Page last updated 07/30/2015 - 8:45am.

  9. Clinical Trials Report for September 2015

    ... the efficacy and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic ...

    Page last updated 08/26/2015 - 1:05pm.

  10. Iron Chelation Therapy

    ... is very effective at reducing iron overload. Deferasirox (Exjade) . Deferasirox is a newer iron chelating medication that comes in a tablet form. ...

    Page last updated 01/20/2015 - 4:40pm.